Frontage Labs acquires stake in ABR

USA-based Frontage Laboratories, a provider of bioanalytical, preclinical and drug development services to the pharmaceutical industry, has acquired a significant equity interest in Advanced Biomedical Research, full-service contract research organization.

With the completion of this initial phase acquisition, the combined resources of the two companies will offer unparalleled formulation development, bioanalytical and GMP testing services, Phase I/II study performance in a state-of-the-art 72-bed clinical research facility and "turn key" multinational Phase II-IV CRO services, noted a Frontage press release.

"Years of partnering with Frontage have already proven the synergies of our combined resources and capabilities," said Michael Willett, chief executive of ABR. "Taking advantage of the opportunity to formally add Frontage's high caliber bioanalytical services and client focused management commitment to ABR's current offerings of clinical trial conduct and CRO services makes good sense for our respective teams as well as our clients. It will enable us to more fully meet the complete spectrum of our clients' needs," he added.